Home Cart Sign in  
Chemical Structure| 1149705-71-4 Chemical Structure| 1149705-71-4

Structure of XL888
CAS No.: 1149705-71-4

Chemical Structure| 1149705-71-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL888 is a specific and ATP-competitive Hsp90 inhibitor with IC50 of 24 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of XL888

CAS No. :1149705-71-4
Formula : C29H37N5O3
M.W : 503.64
SMILES Code : N(C(=O)C1=CC(N[C@@H](CC)C)=C(C(N)=O)C=C1C)[C@H]2C[C@@H]3N([C@H](C2)CC3)C4=CC=C(C(=O)C5CC5)C=N4
MDL No. :MFCD22124888

Safety of XL888

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of XL888

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAF-inhibitor resistant cell lines 300 nM Block ERK1/2 signaling PMC4568562
ESTDAB037 200 nM 72 hours Evaluate the effect of XL888 on the viability of ESTDAB037 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
A375 DR1 200 nM 72 hours Evaluate the effect of XL888 on the viability of A375 DR1 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
MNT-1 DR100 200 nM 72 hours Evaluate the effect of XL888 on the viability of MNT-1 DR100 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
M026R.X1.CL 200 nM 72 hours Evaluate the effect of XL888 on the viability of M026R.X1.CL cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
MNT-1 200 nM 72 hours Evaluate the effect of XL888 on the viability of MNT-1 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
A375 200 nM 72 hours Evaluate the effect of XL888 on the viability of A375 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
SK-Mel 28 200 nM 72 hours Evaluate the effect of XL888 on the viability of SK-Mel 28 cells, results showed that XL888 did not significantly reduce cell viability. PMC5836539
SK-Mel 24 200 nM 72 hours Evaluate the effect of XL888 on the viability of SK-Mel 24 cells, results showed that XL888 significantly reduced cell viability. PMC5836539
Human lung fibroblasts (IPF patients) 1 μM 5 days XL888 preferentially targeted p16INK4a-hi fibroblasts, reducing their count PMC11060735
Mouse lung fibroblasts 1 μM 3 days Screening for compounds targeting p16Ink4a+ fibroblasts, XL888 significantly reduced GFP+ fibroblast count PMC11060735
NRAS mutant melanoma cell lines (M245, M318, WM1361A, WM1366) 300 nM 24-72 hours XL888 treatment led to the degradation of ARAF, CRAF, Wee1, Chk1, and cdc2, and was associated with decreased MAPK, AKT, mTOR, and JNK signaling. Apoptosis induction was associated with increased BIM expression and a decrease in the expression of the pro-survival protein Mcl-1. PMC3683468
NRAS mutant melanoma cell lines (WM852, WM1346, WM1361A, WM1366, WMSbCl2, M202, M207, M244, M245, M318) 1nM – 30 µM 72 hours XL888 inhibited the growth of NRAS mutant melanoma cells in a concentration-dependent manner and induced G2/M phase cell cycle arrest and apoptosis. PMC3683468
NRAS mutant melanoma cell lines (M245, M318, WM1361A, WM1366) 300 nM 48 hours XL888 treatment led to the degradation of ARAF, CRAF, Wee1, Chk1, and cdc2, and was associated with decreased MAPK, AKT, mTOR, and JNK signaling. Apoptosis induction was associated with increased BIM expression and a decrease in the expression of the pro-survival protein Mcl-1. PMC4083119
HRAS Q61L-transduced NIH3T3 cells 300nM 72 hours XL888 suppressed vemurafenib-driven MAPK signaling and decreased CRAF expression PMC4567904
NRAS mutant melanoma cell lines 300nM 72 hours XL888 suppressed vemurafenib-induced paradoxical MAPK activation and decreased CRAF expression PMC4567904
NRAS mutant/wild-type BRAF cell lines >100 nM Reverse paradoxical activation of ERK1/2 induced by vemurafenib PMC4568562

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Lung fibrosis model Oral 62.5 mg/kg 5 days a week for 2 weeks XL888 significantly reduced p16Ink4a+ fibroblast count in a murine model of lung fibrosis and attenuated fibrotic burden PMC11060735
BALB SCID mice NRAS mutant melanoma xenograft model (M245 cells) Oral gavage 125 mg/kg 3 times per week for 18 days XL888 treatment significantly slowed tumor growth (P=0.017) and induced tumor cell apoptosis (detected by TUNEL staining). In vivo studies showed that XL888 led to the degradation of CDK4 and Wee1 and inhibition of AKT/S6 signaling. PMC3683468
SCID mice NRAS mutant M245 melanoma xenograft model Oral gavage 100 mg/kg Three times per week for 15 days Evaluate the anti-tumor efficacy of XL888 in vivo. Results showed XL888 significantly reduced tumor volume and increased HSP70 expression. PMC4083119
C57BL/6 mice Subcutaneous Panc02 tumor model Oral 62.5mg/kg 3 times per week for 2 weeks Combination therapy with XL888 and anti-PD-1 antibody significantly inhibited tumor growth and increased infiltration of CD8+ and CD4+ T cells PMC7790996
Mice SK-MEL-28 xenograft model Oral 35mg, 45mg, 90mg, 135mg PO BIW Twice weekly for 24 weeks Reduce the number of hyperproliferative/neoplastic skin lesions PMC4568562

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00796484 Cancer PHASE1 TERMINATED 2025-11-10 Hospital of the University of ... More >>Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.93mL

1.99mL

0.99mL

19.86mL

3.97mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories